Figure_8.tif (2.62 MB)
Lower sphingomyelins and higher ceramides in Alzheimer's patients are independent of statin use.
figure
posted on 2013-02-20, 16:51 authored by Xianlin Han, Steve Rozen, Stephen H. Boyle, Caroline Hellegers, Hua Cheng, James R. Burke, Kathleen A. Welsh-Bohmer, P. Murali Doraiswamy, Rima Kaddurah-DaoukPanel A shows the differences in sphingomyelin and ceramide mass levels between AD patients and controls who were taking statins. For this comparison, P = 7×10−4 for sphingomyelins and P = 0.00054 for ceramides (Wilcoxon signed rank test). Panel B shows the differences of sphingomyelin and ceramide mass levels between AD patients and controls who were not taking statins. For this comparison, P = 3.2×10−8 for sphingomyelins and P = 0.0056 for ceramides (Wilcoxon signed rank test).
